IKT-905

N/A

Report date: 2026/03/19 16:53:33

Base Information

Drug NameIKT-905

Drug Alias Nameanti-CD3/anti-glypican-3 bispecific T-cell engager (Icell Kealex)GPC3-TEA-VVIKT-905

ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionGlypican-3 modulatorsImmunostimulantsT lymphocytes stimulants +[4]

TargetsT cell surface glycoprotein CD3Glypican-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesIcell Kealex Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIcell Kealex Therapeutics

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A